Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-31,700
Closed -$768K 318
2025
Q2
$768K Sell
31,700
-2,400
-7% -$56K 0.08% 197
2025
Q1
$864K Sell
34,100
-3,000
-8% -$78.5K 0.1% 185
2024
Q4
$984K Buy
37,100
+4,200
+13% +$114K 0.1% 178
2024
Q3
$952K Buy
32,900
+1,300
+4% +$37.9K 0.1% 175
2024
Q2
$884K Buy
31,600
+2,400
+8% +$66.1K 0.24% 92
2024
Q1
$810K Buy
29,200
+3,100
+12% +$86K 0.24% 98
2023
Q4
$751K Buy
26,100
+2,600
+11% +$78.6K 0.23% 102
2023
Q3
$779K Buy
23,500
+3,700
+19% +$131K 0.27% 93
2023
Q2
$726K Hold
19,800
0.26% 102
2023
Q1
$808K Buy
+19,800
New +$855K 0.34% 76
2021
Q4
Sell
-5,000
Closed -$215K 404
2021
Q3
$215K Buy
+5,000
New +$222K 0.09% 152
2020
Q2
Sell
-13,386
Closed -$415K 375
2020
Q1
$415K Sell
13,386
-209,219
-94% -$7.13M 0.09% 166
2019
Q4
$8.28M Buy
+222,605
New +$7.93M 1.17% 32

Other funds holding PFE

Denali Advisors's PFE Position: Q3 2025 in Review

Denali Advisors sold out of Pfizer (PFE) in Q3 2025, closing a stake of 31,700 shares — an estimated $768K sold.

Denali Advisors first reported a position in PFE in Q4 2019 and held it in 13 quarters. The position peaked at $8.28M in Q4 2019. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Denali Advisors reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Denali Advisors sold 31,700 Pfizer shares in Q3 2025, an estimated $768K.
  • Denali Advisors first reported a position in Pfizer in Q4 2019 and held it in 13 quarters.
  • Denali Advisors's Pfizer position peaked at $8.28M in Q4 2019.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Denali Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.